Abstract
Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.
| Original language | English |
|---|---|
| Pages (from-to) | 3-9 |
| Number of pages | 7 |
| Journal | American Journal of Clinical Dermatology |
| Volume | 11 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - Jul 9 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Etanercept : An evolving role in psoriasis and psoriatic arthritis. / Prodanovich, Srdjan; Ricotti, Carlos; Glick, Brad P.; Inverardi, Luca A; Leonardi, Craig L.; Kerdel, Francisco.
In: American Journal of Clinical Dermatology, Vol. 11, No. SUPPL. 1, 09.07.2010, p. 3-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Etanercept
T2 - An evolving role in psoriasis and psoriatic arthritis
AU - Prodanovich, Srdjan
AU - Ricotti, Carlos
AU - Glick, Brad P.
AU - Inverardi, Luca A
AU - Leonardi, Craig L.
AU - Kerdel, Francisco
PY - 2010/7/9
Y1 - 2010/7/9
N2 - Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.
AB - Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.
UR - http://www.scopus.com/inward/record.url?scp=77954276700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954276700&partnerID=8YFLogxK
U2 - 10.2165/1153413-S0-000000000-00000
DO - 10.2165/1153413-S0-000000000-00000
M3 - Article
VL - 11
SP - 3
EP - 9
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - SUPPL. 1
ER -